Scripps Clinical Hematology and Oncology 2026

Introduction

The Scripps Clinical Hematology and Oncology 2026 program is a comprehensive cancer medicine conference designed to deliver the latest clinical advances in hematology, medical oncology, targeted therapeutics, and multidisciplinary cancer care. Presented by Scripps Cancer Center, the course brings together nationally recognized experts to review evolving standards of care, molecular diagnostics, immunotherapies, hematologic malignancies, and solid tumor management.

Recognized as one of the largest hematology and oncology educational meetings in the Western United States, the conference provides a uniquely integrated curriculum covering both hematologic and oncologic diseases within a single evidence-based educational platform.

The curriculum integrates:

• Hematologic malignancies
• Solid tumor oncology
• Breast cancer management
• Molecular oncology
• Targeted cancer therapies
• Immunotherapy
• Precision medicine
• Diagnostic hematopathology
• Evidence-based oncology care
• Multidisciplinary cancer management

into a clinically practical educational experience designed to improve cancer diagnosis, treatment selection, and patient outcomes.

---

Course Overview

📚 Program: Scripps Clinical Hematology and Oncology 2026

🏛️ Presented by Scripps Cancer Center

📅 Course Date: 2026

🎥 Included Content

• 42 video lectures
• 42 subtitle VTT files
• 31 PDF presentations

💾 Course Size: 23 GB

🎓 Educational Format

• Expert-led oncology lectures
• Evidence-based cancer education
• Multidisciplinary panel discussions
• Clinical case-based learning
• Hematology and oncology updates

The conference provides advanced education spanning both malignant hematology and solid tumor oncology.

---

Educational Focus

The program focuses on:

• Clinical hematology
• Medical oncology
• Hematologic malignancies
• Solid tumor management
• Breast cancer therapeutics
• Molecular diagnostics
• Immunotherapy
• Targeted cancer therapies
• Precision oncology
• Evidence-based cancer care

The curriculum emphasizes practical implementation of evolving cancer therapies and modern multidisciplinary oncology management.

---

Learning Objectives

After completing this activity, learners strengthen their ability to:

• Explain molecular and clinical mechanisms underlying hematologic disorders
• Apply modern diagnostic methods in hematology and oncology
• Implement evidence-based treatment approaches for hematologic malignancies
• Evaluate targeted therapies and immunotherapies for common cancers
• Incorporate contemporary strategies for solid tumors and breast cancer management
• Interpret prognostic and therapeutic oncology data
• Apply multidisciplinary approaches to complex hematology and oncology cases
• Utilize clinical insights from case-based panel discussions in real-world cancer care

The educational material combines translational oncology science with practical patient-centered clinical management.

---

Hematologic Disorders & Malignancies

A major component of the conference focuses on modern hematology and malignant blood disorders.

Covered Areas

• Hematologic malignancies
• Diagnostic hematology
• Molecular hematopathology
• Leukemia and lymphoma management
• Evidence-based hematology therapeutics
• Advances in blood cancer treatment

The curriculum reviews evolving standards of care and emerging therapies in hematologic disease.

---

Solid Tumor Oncology

Dedicated educational sessions review current approaches to common and complex solid tumors.

Topics Include

• Solid tumor diagnostics
• Prognostic evaluation
• Systemic cancer therapy
• Precision oncology
• Multidisciplinary cancer management
• Advanced therapeutic strategies

Participants strengthen practical understanding of modern oncologic treatment planning.

---

Breast Cancer Management

Specialized sessions address advances in breast oncology from diagnosis through treatment.

Educational Topics

• Breast cancer therapeutics
• Molecular profiling
• Prognostic assessment
• Personalized treatment strategies
• Emerging systemic therapies

The sessions highlight evidence-based approaches to contemporary breast cancer care.

---

Targeted Therapies & Precision Oncology

The conference strongly emphasizes evolving molecular and personalized treatment strategies.

Covered Areas

• Targeted cancer therapies
• Precision medicine
• Biomarker-driven treatment
• Molecular oncology
• Personalized therapeutic selection
• Contemporary oncology pharmacology

The curriculum reviews how evolving molecular insights influence individualized cancer management.

---

Immunotherapy & Emerging Cancer Treatments

A central educational focus involves rapidly evolving immunotherapeutic approaches.

Topics Include

• Cancer immunotherapy
• Novel therapeutic strategies
• Immune-related treatment considerations
• Advanced oncology therapeutics
• Emerging clinical evidence

Participants gain practical insight into modern immuno-oncology approaches across multiple malignancies.

---

Multidisciplinary Cancer Care

The educational content highlights collaborative management strategies across oncology specialties.

Educational Themes

• Multidisciplinary oncology collaboration
• Integrated cancer care pathways
• Evidence-based treatment planning
• Tumor board–style clinical reasoning
• Complex oncology case management

The program emphasizes coordinated patient-centered cancer care.

---

Clinical Case Discussions & Panel Learning

A defining feature of the conference is the integration of practical clinical scenarios.

Included Features

• Interactive panel discussions
• Evidence-based case reviews
• Real-world oncology management
• Diagnostic and therapeutic problem-solving
• Practical cancer care applications

The sessions reinforce translation of current oncology evidence into clinical practice.

---

Educational Experience

The conference combines:

• Expert-led hematology lectures
• Advanced oncology education
• Case-based clinical learning
• Evidence-based therapeutic reviews
• Multidisciplinary cancer discussions
• Molecular and translational oncology updates

The educational format emphasizes practical and clinically relevant oncology education.

---

Why This Conference Stands Out

Integrated Hematology & Oncology Curriculum

One of the few major conferences combining comprehensive hematology and oncology education in a single program.

Strong Precision Medicine Focus

Highlights targeted therapies, molecular diagnostics, and biomarker-driven cancer care.

Evidence-Based Clinical Education

Integrates evolving oncology guidelines, emerging research, and practical management strategies.

Multidisciplinary Oncology Perspective

Brings together expertise across hematology, medical oncology, surgery, and radiation oncology.

Practical Case-Based Learning

Emphasizes real-world application of oncology evidence through interactive clinical discussions.

---

Clinical Value

The Scripps Clinical Hematology and Oncology 2026 program delivers advanced cancer medicine education through integrated coverage of:

• Hematologic malignancies
• Clinical hematology
• Solid tumor oncology
• Breast cancer management
• Molecular diagnostics
• Precision oncology
• Targeted therapies
• Cancer immunotherapy
• Personalized cancer treatment
• Evidence-based oncology care
• Multidisciplinary cancer management
• Clinical oncology case discussions

The combination of expert-led instruction, molecular oncology education, practical therapeutic updates, and multidisciplinary cancer care strategies makes this conference highly valuable for clinicians involved in modern hematology and oncology practice.

4. Topics

1. 01 Platelet-Activating Anti-PF4 Disorders

2. 02 ITP 2026 Update

3. 03 Transfusion Medicine for the Practicing Hem-Onc Physician

4. 04 Panel DiscussionQ&A

5. 05 Unusual Thromboses

6. 06 Anticoagulants and Antiplatelet Agents When to Combine and When not to

7. 07 VTE and Anticoagulation 2026 Update

8. 08 Panel DiscussionQ&A

9. 09 Breakout 1 Interesting Cases in Thrombosis

10. 10 Breakout 2 Interesting Cases in Platelet Disorders

11. 11 Breakout 3 Interesting Cases in Bleeding

12. 12 Breakout 4 Interesting Cases in Plasma Cell Dyscrasias

13. 13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Janice Mehnert, MD

14. 13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Ryan Sullivan, MD

15. 13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs -Allison Betof-Warner, MD, PhD

16. 14 Panel DiscussionQ&A

17. 15 Menin Inhibitors and Other New Targeted Therapies in AML

18. 16 Hypomethylating Agents and Beyond Cutting-Edge Approaches to MDS

19. 17 After IMiDs, Proteosome Inhibitors, and CD38 Antibodies Novel Approaches to RelapsedRefractory Multiple Myeloma

20. 18 Panel DiscussionQ&A

21. 19 Newer Therapeutic Options for Refractory or Relapsed Large Cell Lymphoma

22. 20 Non-Chemotherapy Approaches to Mantle Cell Lymphoma

23. 21 Progress in the Treatment of AL Amyloidosis

24. 22 Panel DiscussionQ&A

25. 23 Beyond BRCA Managing Risk in Women with Moderate-Penetrance Gene Mutations

26. 24 Advances in the Treatment of Metastatic Triple-Negative Breast Cancer

27. 25 Minimal Residual Disease, Disease Monitoring, and Therapy Selection What is the Evidence-Based role for ctDNA in Breast Cancer Therapy

28. 26 Panel DiscussionQ&A

29. 27 Neo-Adjuvant Chemo-Immunotherapy in Resectable NSCLC A New Standard of Care

30. 28 Therapy Beyond First-Line Therapy in EGFR Mutated NSCLC

31. 29 Comparing the Harms and Benefits of Chemo-Immunotherapy or Immunotherapy Alone in the Metastatic Setting

32. 30 Panel DiscussionQ&A

33. 31 Checkpoint Immune Therapy in the Curative Settings of GI Cancers

34. 32 Are TTFs and Novel Small Molecules Moving the Needle in Pancreatic Cancer

35. 33 Panel DiscussionQ&A

36. 34 De-Escalation Strategies in HPV Positive Head and Neck Cancer

37. 35 Cervical Cancer Updates

38. 36 Molecular Classification and Treatment Opportunities in Brain Tumors

39. 37 Panel DiscussionQ&A

40. 38 Optimizing Bone Health in Cancer Care During and After Treatment

41. 39 Management of Common Skin Related Side Effects During and After Cancer Treatment

42. 40 Panel DiscussionQ&A